76 related articles for article (PubMed ID: 3555061)
1. Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model.
Dudley MN; Mandler HD; Gilbert D; Ericson J; Mayer KH; Zinner SH
Am J Med; 1987 Apr; 82(4A):363-8. PubMed ID: 3555061
[TBL] [Abstract][Full Text] [Related]
2. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
Nix DE; Sands MF; Peloquin CA; Vari AJ; Cumbo TJ; Vance JW; Fracasso JE; Schentag JJ
Am J Med; 1987 Apr; 82(4A):352-6. PubMed ID: 3555060
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ciprofloxacin in stationary-phase bacteria in vivo.
Zeiler HJ; Voigt WH
Am J Med; 1987 Apr; 82(4A):87-90. PubMed ID: 3107381
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial activity of ciprofloxacin administered intravenously in a pharmacodynamic in vitro model.
Esposito S; Jansen A
Int J Clin Pharmacol Res; 1991; 11(4):193-9. PubMed ID: 1813438
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
Burgess DS; Summers KK; Hardin TC
Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses.
Bergan T; Thorsteinsson SB; Solberg R; Bjornskau L; Kolstad IM; Johnsen S
Am J Med; 1987 Apr; 82(4A):97-102. PubMed ID: 3578334
[TBL] [Abstract][Full Text] [Related]
9. An overview of the pharmacology of intravenously administered ciprofloxacin.
Drusano GL
Am J Med; 1987 Apr; 82(4A):339-45. PubMed ID: 3578325
[TBL] [Abstract][Full Text] [Related]
10. Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections.
Lorian V; Pavletich K
Drugs Exp Clin Res; 1994; 20(5):209-14. PubMed ID: 7875058
[TBL] [Abstract][Full Text] [Related]
11. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of ciprofloxacin alone and in combination with other antibiotics in a murine model of thigh muscle infection.
Haller I
Am J Med; 1987 Apr; 82(4A):76-9. PubMed ID: 3578333
[TBL] [Abstract][Full Text] [Related]
13. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics.
Nix DE; Cumbo TJ; Kuritzky P; DeVito JM; Schentag JJ
Am J Med; 1987 Apr; 82(4A):146-53. PubMed ID: 3555029
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients.
Guay DR; Awni WM; Peterson PK; Obaid S; Breitenbucher R; Matzke GR
Am J Med; 1987 Apr; 82(4A):124-9. PubMed ID: 3578321
[TBL] [Abstract][Full Text] [Related]
15. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
Lister PD; Wolter DJ
Clin Infect Dis; 2005 Feb; 40 Suppl 2():S105-14. PubMed ID: 15712098
[TBL] [Abstract][Full Text] [Related]
16. Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria.
Chin NX; Neu HC
Am J Med; 1987 Apr; 82(4A):58-62. PubMed ID: 3578330
[TBL] [Abstract][Full Text] [Related]
17. Ciprofloxacin: an update on clinical experience.
Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Becker N; August R
Am J Med; 1987 Apr; 82(4A):381-6. PubMed ID: 3555063
[TBL] [Abstract][Full Text] [Related]
18. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
20. Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin.
Scully BE; Jules K; Chin NX; Neu HC
Am J Med; 1987 Apr; 82(4A):336-8. PubMed ID: 3578324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
